Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adverse events and changes in disease activity of subcutaneous epcoritamab in combination with oral and intravenous anti-neopl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING